Your browser doesn't support javascript.
loading
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis, H; Herold, T; Ting, S; Worm, K; Huber, U; Christoph, D C; Eberhardt, W E; Kostbade, K; Kasper, S; Stamatis, G; Welter, S; Darwiche, K; Karpf-Wissel, R; Theegarten, D; Schmid, K W; Schuler, M; Wiesweg, M.
Afiliação
  • Reis H; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Herold T; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany; German Cancer Research Center, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
  • Ting S; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Worm K; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Huber U; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Christoph DC; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Eberhardt WE; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany; Division of Thoracic Oncology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, 45239 Essen, Germany.
  • Kostbade K; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Stamatis G; Division of Thoracic Surgery, Ruhrlandklinik, West German Lung Center, University Hospital Essen, 45239 Essen, Germany.
  • Welter S; Division of Thoracic Surgery, Ruhrlandklinik, West German Lung Center, University Hospital Essen, 45239 Essen, Germany.
  • Darwiche K; Division of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, 45239 Essen, Germany.
  • Karpf-Wissel R; Division of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, 45239 Essen, Germany.
  • Theegarten D; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Schmid KW; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
  • Schuler M; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany; Division of Thoracic Oncology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, 45239
  • Wiesweg M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
Lung Cancer ; 88(1): 34-41, 2015 Apr.
Article em En | MEDLINE | ID: mdl-25708529
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Biomarcadores Tumorais / Receptor ErbB-2 / Fosfatidilinositol 3-Quinases / Neoplasias Pulmonares Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Biomarcadores Tumorais / Receptor ErbB-2 / Fosfatidilinositol 3-Quinases / Neoplasias Pulmonares Idioma: En Ano de publicação: 2015 Tipo de documento: Article